



**Sterne Kessler
Goldstein Fox**
ATTORNEYS AT LAW

Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr
Michael V. Messenger
Judith U. Kim
Patrick E. Garrett

Jeffrey T. Helvey
Eldora L. Ellison
Thomas C. Fiala
Donald R. Banowitz
Peter A. Jackman
Jeffrey S. Weaver
Brian J. Del Buono
Mark Fox Evens
Edward W. Yee
Vincent L. Capuano
Virgil Lee Beaton
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Daniel A. Klein
Jason D. Eisenberg
Michael D. Specht

Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longworth
Lori A. Gordon
Laura A. Vogel
Bryan S. Wade
Bashir M.S. Ali
Shannon A. Carroll
Anbar F. Khal
Michelle K. Holoubek
Marsha A. Rose
Young Tang
Christopher J. Walsh

W. Blake Coblenz*
James J. Pohl*
John T. Haran
Mark W. Rygiel
Kevin W. McCabe
Michael R. Malek*

Registered Patent Agents*
Karen R. Markowicz
Matthew J. Dowd
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Victoria S. Rutherford
Simon J. Elliott
Julie A. Heider
Mita Mukherjee

Scott M. Woodhouse
Liliana Di Nola-Baron
Peter A. Socarras
Jeffrey K. Mills
Danielle L. Letting
Lori Brandes
Steven C. Oppenheimer

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

September 1, 2006

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

WRITER'S DIRECT NUMBER:
(202) 772-8575
INTERNET ADDRESS:
MMUKHERJ@SKGF.COM

Art Unit 1644

Attn: Mail Stop Amendment

Re: U.S. Utility Patent Application
Application No. 09/350,401; Filed: July 8, 1999
For: **Inducing Cellular Immune Responses to Hepatitis B Virus Using
Peptide and Nucleic Acid Compositions**
Inventors: SETTE *et al.*
Our Ref: 2473.0060008/PAJ/M-M

Sir:

Transmitted herewith for appropriate action are the following documents:


1. Response to Notice of Non-Compliant Amendment (37 C.F.R. § 1.121);
2. Replacement Table XXIV (Appendix A); and
3. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


Mita Mukherjee
Agent for Applicants
Registration No. 54,325

PAJ/M-M:krh
Enclosures

573376_1.DOC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Sette *et al.*

Appl. No.: 09/350,401

Filed: July 8, 1999

For: **Inducing Cellular Immune
Responses to Hepatitis B Virus
Using Peptide and Nucleic Acid
Compositions**



Confirmation No.: 8008

Art Unit: 1644

Examiner: Schwadron, Ronald B.

Atty. Docket: 2473.0060008/PAJ/M-M

Response to Notice of Non-Compliant Amendment (37 C.F.R. § 1.121)

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In reply to the Notice of Non-Compliant Amendment dated August 2, 2006, Applicants submit a replacement Table XXIV originally submitted on April 2, 2001. In accordance with the Notice of Non-Compliant Amendment, Applicants are only resubmitting Table XXIV, which is the only section identified in the Notice requiring correction.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefore (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.